Blueshift Asset Management LLC Invests $294,000 in Edwards Lifesciences Co. (NYSE:EW)

Blueshift Asset Management LLC acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 4,457 shares of the medical research company’s stock, valued at approximately $294,000.

A number of other large investors also recently bought and sold shares of the business. First Community Trust NA acquired a new stake in Edwards Lifesciences in the second quarter valued at approximately $29,000. Webster Bank N. A. purchased a new position in Edwards Lifesciences during the 2nd quarter worth $39,000. Versant Capital Management Inc grew its stake in Edwards Lifesciences by 206.3% during the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after buying an additional 326 shares during the last quarter. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences in the third quarter valued at about $32,000. Finally, Avior Wealth Management LLC raised its stake in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,262,521.36. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,000 shares of company stock valued at $2,657,000 in the last three months. 1.27% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $72.07 on Friday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm’s 50 day moving average price is $68.01 and its 200-day moving average price is $75.32. The firm has a market cap of $42.51 billion, a P/E ratio of 10.40, a P/E/G ratio of 4.01 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period last year, the business posted $0.59 earnings per share. As a group, equities research analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on EW. Barclays cut their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Oppenheimer restated an “outperform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Wells Fargo & Company lowered their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Evercore ISI cut their target price on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Finally, Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $76.85.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.